1128 Objectives: Blockade of the dopamine D 2 receptor is an essential mechanism of
action of antipsychotic drugs. Positron emission tomography (PET) studies have …

The use of so-called, atypical antipsychotic medication is becoming more widespread in the
treatment of psychotic disorders. EMD 128 130 is a novel compound acting as an agonist at …

The effect of reserpine induced dopamine depletion on the binding of the putative dopamine-
D3 receptor ligand,[11C] RGH-1756 was examined in the monkey brain with positron …

The dopamine-D3 receptor is of special interest due to its postulated role in the
pathophysiology and treatment of schizophrenia and Parkinson's Disease. Increasing …

Context Most antipsychotics are thought to have an effect on D 2 and D 3 receptors. The
development of carbon 11–labeled (+)-4-propyl-9-hydroxynaphthoxazine ([11 C]-(+)-PHNO) …

Positron emission tomography (PET) antagonist ligands such as [11C]‐raclopride are
commonly used to study dopamine D2 receptor (D2) binding of antipsychotics. It has been …

The dopamine D4 receptor (D4R) is expressed in low density in various extrastriatal brain
regions. This receptor subtype is discussed in relation to the pathophysiology and treatment …

Dopamine D3 receptors are preferentially localized in the limbic system and midbrain, and
thus may be involved in the pathophysiology of neuropsychiatry disorders.[11C](+)-PHNO is …

The dopamine D3 receptor is expressed in low density in limbic brain areas. The receptor
subtype has been proposed as a target for novel antipsychotic drugs, however no selective …

399 Objectives: YKP1358 is a novel serotonin (5-HT 2A) and dopamine (D 2) antagonist,
and fitted the general profile of an atypical neuroleptic agent in preclinical studies. The time …